What one share of Corvus Pharmaceuticals holds
We are a clinical stage biopharmaceutical company developing product candidates that precisely target proteins that are critical to immune cell maturation and function. We believe our proprietary product candidates have broad potential to address immune mediated diseases, inflammatory diseases and cancers.
Corvus Pharmaceuticals’s numbers from its SEC filings, divided by its shares. Results cover the last 12 months to 2026-06-30; the balance sheet is as of 2026-06-30.
| Profit | −$0.62 |
|---|---|
| Capex (buildings and equipment) | $0.01 |
| Free cash flow | −$0.52 |
| Cash and investments | $0.22 |
| Book value | $2.68 |
Per share by fiscal year
| Year | Sales | Profit | Capex | Free cash | Dividends | Book value |
|---|---|---|---|---|---|---|
| 2015 | — | −$83.86 | $4.68 | −$34.99 | — | — |
| 2016 | — | −$2.36 | $0.14 | −$1.95 | — | $6.35 |
| 2017 | — | −$2.72 | $0.01 | −$2.27 | — | $4.03 |
| 2018 | — | −$1.71 | $0.01 | −$1.50 | — | $3.76 |
| 2019 | — | −$1.59 | $0.00 | −$1.27 | — | $2.54 |
| 2020 | — | −$0.20 | $0.00 | −$1.18 | — | $2.54 |
| 2021 | — | −$1.03 | $0.00 | −$0.88 | — | $2.09 |
| 2022 | — | −$0.89 | $0.01 | −$0.59 | — | $1.21 |
| 2023 | — | −$0.56 | $0.00 | −$0.50 | — | $0.79 |
| 2024 | — | −$1.02 | — | — | — | $0.48 |
| 2025 | — | −$0.53 | $0.00 | −$0.41 | — | $0.82 |
Common questions about Corvus Pharmaceuticals
How much does one share of Corvus Pharmaceuticals earn?
Over the last 12 months, Corvus Pharmaceuticals lost $0.62 for each share.
Does Corvus Pharmaceuticals pay a dividend?
Corvus Pharmaceuticals didn’t pay a dividend over the last 12 months, according to its SEC filings.
What is Corvus Pharmaceuticals’s book value per share?
Corvus Pharmaceuticals’s book value is $2.68 per share: what would be left for each share if it sold everything at the values on its books and paid every debt, as of June 30, 2026.
How much cash and debt does each share of Corvus Pharmaceuticals have?
Each share of Corvus Pharmaceuticals has $0.22 of cash and investments, as of June 30, 2026.
What is Corvus Pharmaceuticals’s free cash flow per share?
−$0.52 per share over the last 12 months. Free cash flow is the cash left over after spending on buildings and equipment.
Has Corvus Pharmaceuticals bought back shares?
Corvus Pharmaceuticals’s share count rose about 21242% from 2015 to 2025. That dilution means each share owns a smaller slice of the company.
From its SEC filings. For education only, not investment advice. New to these words? See the StockSlicer glossary.